[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-326961-105":59,"doc-detail-326961-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","parp1-targeted-fluorescence-molecular-endoscopy-as-novel-tool-for-early-detection-of-esophageal-dysplasia-and-adenocarcinoma","PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma","","Esophageal cancer is among the most common cancers worldwide, and incidence continues to rise. Current surveillance using white-light endoscopy and random biopsies (Seattle protocol) misses dysplastic and cancerous lesions in up to 50% of patients, motivating tumor-specific imaging approaches. This study evaluates PARPi-FL, a PARP1-inhibitor fluorescent probe, for early detection in patient-derived organoids and transgenic mouse models that model Barrett’s esophagus to esophageal adenocarcinoma transformation. PARP1 expression and PARPi-FL uptake were assessed, with fluorescence molecular endoscopy validating accumulation in dysplastic lesions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/parp1-targeted-fluorescence-molecular-endoscopy-as-novel-tool-for-early-detection-of-esophageal-dysplasia-and-adenocarcinoma/326961/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/parp1-targeted-fluorescence-molecular-endoscopy-as-novel-tool-for-early-detection-of-esophageal-dysplasia-and-adenocarcinoma/326961.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this research address in esophageal cancer surveillance?","Question",{"text":112,"@type":113},"The study targets the limitation of current surveillance with white-light endoscopy and random biopsies, which fails to diagnose dysplastic and cancerous lesions in up to 50% of patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PARPi-FL relate to the biology of the lesions?",{"text":117,"@type":113},"PARPi-FL is a fluorescent PARP1-inhibitor probe, and it localizes to PARP1-expressing epithelial cell nuclei, enabling imaging of dysplastic and cancer-related changes.",{"name":119,"@type":110,"acceptedAnswer":120},"What validation was used to confirm fluorescence imaging findings?",{"text":121,"@type":113},"Fluorescence imaging results were validated with confocal microscopy and immunohistochemistry (IHC) of excised tissues.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},326961,1790374339,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Marcazzan etal. J Exp Clin Cancer Res (2024) 43:53  \n[https://doi.org/10.1186/s13046-024-02963-7](https://doi.org/10.1186/s13046-024-02963-7)  \nJournal of Experimental & Clinical Cancer Research  \n RESEARCH Open Access  \nPARP1-targeted fluorescence molecular  \nendoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma  \nSabrina Marcazzan 1,2,11† , Marcos J. Braz Carvalho1†, NghiaT. Nguyen3,4, Julia Strangmann5,  \nJulia Slotta‑Huspenina6, Anna Tenditnaya2 , Markus Tschurtschenthaler4,9,10 , Jonas Rieder5, Andrea Proaño‑Vasco5, Vasilis Ntziachristos2, Katja Steiger6,8 , Dimitris Gorpas2 , Michael Quante5* and Susanne Kossatz3,4,7*  \nAbstract  \nBackground Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random untargeted biopsies collection (Seattle protocol) fails to diagnose dysplastic and cancerous lesions in up to 50% of patients. Therefore, new endoscopic imaging technologies in combination with tumor‑specific molecular probes are needed to improve early detection. Herein, we investigated the use of the fluorescent Poly (ADP‑ribose) Poly‑ merase 1 (PARP1)‑inhibitor PARPi‑FL for early detection of dysplastic lesions in patient‑derived organoids and trans‑ genic mouse models, which closely mimic the transformation from non‑malignant Barrett’s Esophagus (BE) to inva‑ sive esophageal adenocarcinoma (EAC) .  \nMethods We determined PARP1 expression via immunohistochemistry (IHC) in human biospecimens and mouse tissues. We also assessed PARPi‑FL uptake in patient‑ and mouse‑derived organoids. Following intravenous injection of 75 nmol PARPi‑FL/mouse in L2‑IL1B (n = 4) and L2‑IL1B/IL8Tg mice (n = 12), we conducted fluorescence molecu‑ lar endoscopy (FME) and/or imaged whole excised stomachs to assess PARPi‑FL accumulation in dysplastic lesions. L2‑IL1B/IL8Tg mice (n = 3) and wild‑type (WT) mice (n = 2) without PARPi‑FL injection served as controls. The imag‑ ing results were validated by confocal microscopy and IHC of excised tissues.  \nResults IHC on patient and murine tissue revealed similar patterns of increasing PARP1 expression in presence of dys‑ plasia and cancer. In human and murine organoids, PARPi‑FL localized to PARP1‑expressing epithelial cell nuclei after 10 min of incubation. Injection of PARPi‑FL in transgenic mouse models of BE resulted in the successful detection of lesions via FME, with a mean target‑to‑background ratio > 2 independently from the disease stage. The localiza‑ tion of PARPi‑FL in the lesions was confirmed by imaging of the excised stomachs and confocal microscopy. Without PARPi‑FL injection, identification of lesions via FME in transgenic mice was not possible.  \n†Sabrina Marcazzan and Marcos J. Braz Carvalho contributed equally to this work.  \n*Correspondence: Michael Quante  \nmichael. quante@uniklinik‑[freiburg.de](freiburg.de)[ ](freiburg.de)Susanne Kossatz  \n[s.kossatz@tum.de](s.kossatz@tum.de)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/b","cbCaicJF4Izflbuu","https://ap.wps.com/l/cbCaicJF4Izflbuu","pdf",3089759,18,"English","# Abstract\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What problem does this research address in esophageal cancer surveillance?\",\"answer\":\"The study targets the limitation of current surveillance with white-light endoscopy and random biopsies, which fails to diagnose dysplastic and cancerous lesions in up to 50% of patients.\"},{\"question\":\"How does PARPi-FL relate to the biology of the lesions?\",\"answer\":\"PARPi-FL is a fluorescent PARP1-inhibitor probe, and it localizes to PARP1-expressing epithelial cell nuclei, enabling imaging of dysplastic and cancer-related changes.\"},{\"question\":\"What validation was used to confirm fluorescence imaging findings?\",\"answer\":\"Fluorescence imaging results were validated with confocal microscopy and immunohistochemistry (IHC) of excised tissues.\"}]","PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma | PDF",1789975866,45]